David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale
David Kirn, an officer at 4D Molecular Therapeutics, Inc. (FDMT), plans to sell 69,076 shares of Class A Common Stock valued at approximately $1.16 million through Goldman Sachs & Co. LLC. This sale is part of a Rule 10b5-1(c) selling plan initiated on January 9, 2026. The filing indicates previous sales by Kirn and details how the shares were acquired, some through private transactions and others via stock options.
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC
Perigon Wealth Management LLC has purchased 146,185 shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) for approximately $1.94 million during the second quarter. Institutional investors and hedge funds collectively own 99.27% of the company, with various firms increasing their stakes. The company's stock is trading up by 19.4% and has a "Moderate Buy" consensus rating from analysts, despite an insider selling off shares and the company reporting an EPS loss.
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock
4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, sold company shares worth $39,567 after exercising stock options. The company's stock has performed well, gaining over 100% in the past year and trading near its 52-week high. These transactions were executed under a pre-arranged 10b5-1 trading plan, and the company continues to receive favorable analyst ratings following positive clinical trial data and strong corporate developments.
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High - Time to Buy?
4D Molecular Therapeutics (NASDAQ:FDMT) recently hit a new 52-week high of $15.03, closing at $14.55, but the company remains unprofitable with a negative EPS. While analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average price target of $29.62, some insiders have been selling shares. Hedge funds have also been adjusting their positions, with institutional investors owning 99.27% of the stock.
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock
Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics, sold shares worth $39,567 on August 13 and 17, 2026, after exercising stock options. The company's stock has seen over 100% gain in the past year, trading near its 52-week high. These transactions were executed under a pre-arranged 10b5-1 trading plan, and the company has also received positive analyst ratings and completed significant trial milestones.
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades
Scott Bizily plans to sell 6,540 shares of 4D Molecular Therapeutics (NASDAQ: FDMT) on August 17, 2026, following the exercise of stock options. This transaction, processed through Morgan Stanley Smith Barney LLC, has an associated value of $79,722.60. The filing also details three previous programmed sales by Bizily under a 10b5-1 trading plan that occurred between June and August 2026.
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics (FDMT), sold 3,270 shares of common stock after exercising options. The transactions occurred on August 13 and August 17, 2026, with sales at $12.00 and $12.20 per share, respectively, and were executed under a Rule 10b5-1 trading plan adopted in January 2026. Bizily's options were exercised at $4.14 per share, and the total pre-tax spread from these transactions was approximately $26,000.
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $35 to $36
This article provides a brief overview of recent analyst ratings for 4D Molecular Therapeutics (FDMT.US), highlighting that analysts have set price targets ranging from $35 to $36. The information suggests a positive outlook from financial experts regarding the company's stock performance.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 35,200 Restricted Stock Units (RSUs) to five new non-executive employees on August 11, 2026. These grants were made under the company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 35,200 Restricted Stock Units (RSUs) to five new non-executive employees on August 11, 2026. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4DMT announced new employment inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). The grants, consisting of stock options and restricted stock units, were made to 11 new employees on August 12, 2026. The options have a 10-year term and vest over four years, while the RSUs vest over three or four years.
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com
H.C. Wainwright has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target, citing positive two-year data from the Phase 2b PRISM trial for its 4D-150 gene therapy. The company has also completed enrollment for its pivotal Phase 3 4FRONT-2 global trial and 4FRONT-1 North American trial, with topline data expected in Q2 and H2 2027, respectively. Shares have surged 64% over the past year, though the company is noted for its volatility and cash burn.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 35,200 Restricted Stock Units (RSUs) to five new non-executive employees on August 11, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on advancing therapeutics for diseases like wet age-related macular degeneration and cystic fibrosis.
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $36.00 price target for 4D Molecular Therapeutics (NASDAQ:FDMT), citing positive two-year data from its Phase 2b PRISM trial for the gene therapy 4D-150. The company is progressing with its pivotal Phase 3 4FRONT-1 and 4FRONT-2 trials, with topline data expected in Q2 and H2 2027, respectively. Despite stock volatility and cash burn, analysts view 4D-150 as a potential breakthrough in retina treatment.
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its second-quarter 2026 financial results, highlighting significant operational achievements including the completion of enrollment for its 4D-150 4FRONT-2 wet AMD Phase 3 trial and positive 2-year data from the PRISM Phase 2b trial. The company also announced a new strategic credit facility for up to $200 million, an upcoming Investor Day, and an estimated cash runway into the second half of 2028.
FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise
A stockholder of 4D Molecular Therapeutics, Inc. (FDMT) has filed to sell 1,635 common shares on NASDAQ, to be issued through the exercise of stock options for cash on August 13, 2026. This filing also discloses previous Rule 10b5-1 plan sales by Scott Bizily in the past three months, including sales of 6,566 shares for $91,924.00 on June 30, 2026, and 9,810 shares for $117,720.00 on June 23, 2026. The transaction is being handled by Morgan Stanley Smith Barney LLC’s Executive Financial Services.
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for wet AMD and DME, including completed enrollment for two Phase 3 trials for 4D-150 and strong two-year data from its PRISM Phase 2b study. The company also secured a $200 million credit facility and expects its current cash position to fund operations into the second half of 2028. Upcoming milestones include further Phase 3 initiations and an Investor Day in October.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) reported a Q2 loss of $1.04 per share, matching Zacks Consensus Estimate, but surpassed revenue estimates significantly with $3.78 million, beating expectations by 142.37%. The company's stock has performed well year-to-date, rising 58.3% against the S&P 500's 13.2% gain, and currently holds a Zacks Rank #3 (Hold).
Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT
Dimensional Fund Advisors LP has increased its stake in 4D Molecular Therapeutics (NASDAQ:FDMT) by 77.3%, purchasing an additional 227,982 shares to bring its total ownership to 522,823 shares, representing 1.0% of the company. Institutional investors now own 99.27% of the stock, while company insiders have recently sold a significant number of shares. Analysts currently give FDMT a "Moderate Buy" rating with a consensus price target of $29.75.
4D Molecular Therapeutics Inc (FDMT) Stock News Today
This article provides current stock information for 4D Molecular Therapeutics Inc (FDMT), noting its recent price dip. It states that more news regarding FDMT's earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for investors to track FDMT stock performance and related updates.
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
4D Molecular Therapeutics Inc (FDMT) is projected to report a loss of $1.02 per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article provides a brief outlook on the company's expected financial performance.
4D Molecular Therapeutics, Inc. (FDMT) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive financial information for 4D Molecular Therapeutics, Inc. (FDMT), a late-stage biotechnology company. It includes real-time stock price, historical data, performance metrics against the S&P 500, analyst ratings,
4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan
David Kirn, a director and officer at 4D Molecular Therapeutics, Inc. (FDMT), sold 26,842 shares of common stock on August 4, 2026, at a weighted average price of $10.2301 per share. This transaction was conducted under a 10b5-1 trading plan established on January 9, 2026. Following the sale, Kirn directly holds 844,895 common shares in the company.
David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock
David Kirn, an insider at 4D Molecular Therapeutics (NASDAQ:FDMT), recently sold 12,415 shares of the company's stock for a total value of $124,770.75, reducing his position by 1.40%. This sale follows several other transactions by Kirn in recent months. Despite missing quarterly EPS expectations, the company's revenue exceeded estimates, and institutional investors hold a significant portion of the stock, with analysts maintaining a "Moderate Buy" rating.
Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History
This article details Ken Fisher's investment in 4D Molecular Therapeutics Inc (FDMT), held through Fisher Asset Management, LLC. As of June 30, 2026, he owns 65,751 shares valued at $874,490, representing 0% of his portfolio. Fisher has made one purchase of FDMT at an average price of $9.74, resulting in an estimated gain of 10.52% on his holdings.
Form 144 4D Molecular Therapeutics For: 4 August By Investing.com
This article from Investing.com announces a Form 144 filing for 4D Molecular Therapeutics (FDMT) on August 4th. The content is brief, primarily serving as a placeholder for the filing information and is surrounded by typical financial news website navigation and market data. The article provides the company's stock symbol and a minimal change in its stock value.
4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares
David Kirn, an insider at 4D Molecular Therapeutics (FDMT), sold 12,415 shares, bringing his total sales over the past year to 187,416 shares with no purchases. This selling activity, coupled with a lack of insider buying and a significant discount to the GuruFocus Value, classifies FDMT as a "Possible Value Trap, Think Twice." Investors are cautioned to weigh the potential upside against the persistent insider selling and inherent risks of a clinical-stage biotechnology company.
FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades
An insider at 4D Molecular Therapeutics, Inc. (FDMT) plans to sell 26,842 Class A shares, valued at approximately $275,398.92, through Goldman Sachs & Co. LLC on or about August 4, 2026. These shares were originally acquired in a private transaction on December 15, 2020. This planned sale follows multiple significant Class A share sales by shareholder David Kirn over the past three months, totaling over $1.7 million.
4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan
David Kirn, President and CEO of 4D Molecular Therapeutics (FDMT), sold 12,415 shares of company stock on August 3, 2026, at a weighted average price of $10.0461 per share. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on January 9, 2026. Following the sale, Kirn directly holds 871,737 shares of FDMT.
Form 144 4D Molecular Therapeutics For: 4 August By Investing.com
This article from Investing.com announces a Form 144 filing for 4D Molecular Therapeutics, specifically for August 4th. The brief notice provides the stock symbol FDMT, which is currently down 0.88%. The content is primarily a placeholder for financial news updates, surrounded by various market data and navigation elements.
4D Molecular Therapeutics (FDMT) to Announce Earnings on Monday
4D Molecular Therapeutics (FDMT) is set to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts expecting a loss of $1.04 per share and revenue of $3.62 million. The company's shares have recently declined by 3.3%, and the stock has an average "Moderate Buy" rating from analysts with a target price of $30.67. Recent insider selling has been observed, while institutional investors hold a significant portion of the company's stock.
Form 144 4D Molecular Therapeutics For: 4 August By Investing.com
This article from Investing.com reports on a Form 144 filing for 4D Molecular Therapeutics (FDMT) for August 4th. The brief piece includes the stock symbol and its current performance (+1.68%). Beyond this, the content primarily consists of market data, news headlines, and navigational elements common to financial news platforms.
FDMT (FDMT) investor David Kirn plans Rule 144 sale of 12,415 shares
David Kirn, a shareholder in 4D Molecular Therapeutics, Inc. (FDMT), has filed a Rule 144 notice to sell 12,415 shares of Class A Common Stock through Goldman Sachs & Co. LLC on or after August 3, 2026. The proposed sale has an aggregate market value of $125,267.35. Kirn has made several other sales of FDMT Class A Common Stock over the past three months, and the shares to be sold were acquired in a private transaction in December 2020.
Janus Henderson Group PLC Acquires 611,276 Shares of 4D Molecular Therapeutics, Inc. $FDMT
Janus Henderson Group PLC increased its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 13.2% in Q1 2026, purchasing an additional 611,276 shares to own over 5.24 million shares, representing 10.04% of the company. Institutional investors now hold 99.27% of the stock, while company insiders have sold 184,811 shares worth approximately $2.08 million in the past 90 days. Despite a quarterly loss of $1.01 per share, 4D Molecular Therapeutics' revenue exceeded expectations, and analysts maintain a consensus "Moderate Buy" rating with an average price target significantly higher than its current share price.
Enterprise value to EBIT forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT
The article provides a financial metric, "Enterprise value to EBIT forward," for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). This information is sourced from TradingView, which offers various financial data and tools for market analysis. The content primarily focuses on presenting this specific financial ratio for the company without further elaborate analysis or commentary.
Price to sales forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT
This article provides financial information for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT), specifically its price to sales forward ratio. It highlights that the market was closed with no trades, and offers a general overview of the company's financial data available on TradingView.
B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target
B. Riley has initiated coverage on 4D Molecular Therapeutics (FDMT) with a "Buy" rating and a price target of $37. This new rating is significantly higher than the current average analyst price target of $28.67 for the company, suggesting a strong positive outlook from B. Riley. The full details of the analysis are available to premium subscribers.
B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target
B. Riley has initiated coverage on 4D Molecular Therapeutics (FDMT) with a "Buy" rating and a price target of $37. The company, a late-stage biotechnology firm, is advancing several therapeutic candidates, including 4D-150 for wet age-related macular degeneration and diabetic macular edema, and 4D-710 for cystic fibrosis lung disease. This positive analyst recommendation follows recent announcements of favorable clinical trial data and strategic financial moves.
B.Riley initiates 4D Molecular Therapeutics stock coverage with buy rating
B.Riley has initiated coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and a price target of $37.00, suggesting substantial upside from its current price and indicating it may be undervalued. The firm views the company's lead candidate, 4D-150, for neovascular AMD as significantly de-risked. Additionally, 4D Molecular Therapeutics has received a Buy rating from H.C. Wainwright and has recently completed enrollment for two Phase 3 trials ahead of schedule, alongside electing new Class III directors.
Enterprise value to EBITDA forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT
This article from TradingView appears to be a financial data page for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). It focuses on the "Enterprise value to EBITDA forward" metric for the company. The content primarily consists of navigation, copyright information, and links to various TradingView features, rather than a detailed analytical article.
FDMT|4D Molecular Therapeutics Inc|Price:10.060|Chg%:+0.450
This analysis of 4D Molecular Therapeutics Inc (FDMT) highlights its strong fundamentals, high growth potential, and fair valuation, with a "Buy" rating from multiple analysts and a target price of $28.22. The company, a late-stage biotechnology firm, is advancing therapies for retinal vascular diseases and cystic fibrosis, reporting significant revenue and net income growth. Despite recent weak stock market performance, its stock is trading sideways between support and resistance, suggesting suitability for range-bound swing trading.
4D Molecular Therapeutics Inc (FDMT) Financial Health: Profitability & Balance Sheet Analysis
4D Molecular Therapeutics Inc (FDMT) has a stable financial status with a financial score of 7.34, ranking 132nd in its industry. The company reported a significant year-over-year revenue increase of 21664.29% to $3.05M and a net profit increase of 43.33%. However, its operational efficiency is low, and key financial data for several categories are not yet disclosed.
4D Molecular Therapeutics, Inc. Revenue Breakdown – NASDAQ:FDMT
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) generated $85.21 million USD in revenue last year, primarily from its Disease-targeted Therapeutics segment. The company's largest contribution by country came from Japan, accounting for $85.00 million USD. This represents a significant increase from the previous year's revenue of $37,000 USD for the same segment.
Exome Asset Management LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT
Exome Asset Management LLC has acquired a new position in 4D Molecular Therapeutics, purchasing 130,564 shares valued at approximately $1.2 million, as institutional investors now own 99.27% of the company. Despite missing earnings per share expectations, 4D Molecular Therapeutics exceeded revenue estimates and holds a "Moderate Buy" consensus rating from analysts with a price target of $29.88. However, company insiders have recently sold shares worth over $2 million.
4D Molecular Therapeutics Inc (FDMT) Income Statement
This article provides the quarterly and annual income statements for 4D Molecular Therapeutics Inc (FDMT), detailing key financial metrics such as total revenue, operating expenses, operating profit, and net income. It also includes an FAQ section explaining how to read the income statement, the difference between quarterly and annual reports, and important metrics for analyzing FDMT stock. The data covers several fiscal years and provides insights into the company's financial performance.
4D Molecular Therapeutics Inc (FDMT) Cash Flow
This article provides a detailed cash flow statement for 4D Molecular Therapeutics Inc (FDMT), covering quarterly and annual data for operating, investing, and financing activities. It presents key financial figures including operating cash flow, net income, capital expenditures, and free cash flow over several fiscal quarters. The content also includes FAQs explaining the definitions and significance of these cash flow components.
4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for 4D Molecular Therapeutics Inc (FDMT). It states that the company has not distributed any dividends over the past five years. The page also shows FDMT's current stock price, market cap, and other financial overview links.
4D Molecular Therapeutics Inc (FDMT) Balance Sheet
This article provides a balance sheet overview for 4D Molecular Therapeutics Inc (FDMT), detailing its financial health through annual and quarterly data. It covers key metrics like cash, assets, liabilities, and shareholders' equity, allowing investors to analyze the company's liquidity, leverage, and return on equity. The report also includes an FAQ section answering common questions about balance sheet components and FDMT's specific financial figures.
4D Molecular Therapeutics Inc (FDMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides a revenue breakdown for 4D Molecular Therapeutics Inc (FDMT), detailing its financial performance by region. As of the latest update, the company has primarily reported revenue of $85.21 million from the United States, with other relevant business segment data not yet disclosed. The page also presents current stock information including its market cap and recent stock performance.
4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Jul 2026
This article provides an updated overview of 4D Molecular Therapeutics (FDMT) short interest data as of July 15, 2026. The company had 11.36 million shares sold short, representing 23.60% of its public float, which is a 14.59% decrease from the previous report. The short interest ratio stands at 15.5 days to cover, indicating a high level of pessimism among investors regarding the stock's future performance despite the recent decrease in short positions.
